Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States

References

• Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA A Cancer J Clin. 2020;70(3):145–164.
   PubMed Web of Science ®Google Scholar
• American Cancer Society [Internet]. Key statistics for colorectal cancer. 2021. [cited 2021 February 19]. Available from: https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
   Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–359.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359–369.
   PubMed Web of Science ®Google Scholar
• Jean GW, Shah SR. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 2008;28(6):742–754.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–345.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [Internet]. FDA approves new dosing regimen for cetuximab. 2021 April 7. [cited 2021 April 20]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-dosing-regimen-cetuximab
   Google Scholar
• Erbitux (cetuximab) [Internet] US prescribing information 2020 November. [cited 2021 April 20]. Available from: https://uspl.lilly.com/erbitux/erbitux.html
   Google Scholar
• Giusti RM, Cohen MH, Keegan P, et al. FDA review of a panitumumab (vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Oncologist. 2009;14(3):284–290.
   PubMed Web of Science ®Google Scholar
• Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15(6):569–579.
   PubMed Web of Science ®Google Scholar
• Hoang T, Kim J. Combining correlated outcomes and surrogate endpoints in a network Meta-analysis of colorectal cancer treatments. Cancers (Basel). 2020;12(9):2663.
   Web of Science ®Google Scholar
• Rai M, Goyal R. Chapter 33 - Pharmacoeconomics in healthcare. In: Vohora D, Singh G, editors. Pharmaceutical medicine and translational clinical research. Boston (MA): Academic Press; 2018. p. 465–472.
   Google Scholar
• Graham CN, Hechmati G, Fakih MG, et al. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. J Med Econ. 2015;18(8):619–628.
   PubMed Web of Science ®Google Scholar
• Fragoulakis V, Papagiannopoulou V, Kourlaba G, et al. Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece. Clin Ther. 2012;34(10):2132–2142.
   PubMed Web of Science ®Google Scholar
• Gravalos Castro C, Pérez-Alcantara F, Gasquet Espuna JA, et al. Study of minimization of panitumumab versus cetuximab costs in combination with first-line and second-line chemotherapy in native KRAS metastatic colorectal cancer in Spain. Pharmacoecon Spanish Res Article. 2014;11(4):135–145.
   Google Scholar
• Matsuda A, Yamada T, Jamjittrong S, et al. Comparison between biweekly and weekly cetuximab in patients with metastatic colorectal cancer: a Meta-analysis. Anticancer Res. 2020;40(6):3469–3476.
   PubMed Web of Science ®Google Scholar
• Hubbard JM, Alberts SR. Alternate dosing of cetuximab for patients with metastatic colorectal cancer. Gastrointest Cancer Res. 2013;6(2):47–55.
   PubMedGoogle Scholar
• Tabernero J, Ciardiello F, Rivera F, et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol. 2010;21(7):1537–1545.
   PubMed Web of Science ®Google Scholar
• Parikh A, Gugel EG, Smolyakova N, et al. 455P a Meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing. Ann Oncol. 2020;31:S435.
   PubMed Web of Science ®Google Scholar
• Agg H, Han Y, Cui ZL. Real-world data on overall survival associated with biweekly versus weekly cetuximab among metastatic colorectal cancer (mCRC) patients in the United States. J Clin Oncol. 2021;39(3):33–33. (
   Web of Science ®Google Scholar
• Kasper S, Foch C, Messinger D, et al. Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2021;144:291–301.
   PubMed Web of Science ®Google Scholar
• International Society for Pharmacoeconomics and Outcomes Research. Good practices. [accessed on March 2021]. Available from: https://www.ispor.org/heor-resources/good-practices/report-other-report-types/-in-category/index-types/ispor-good-practices-for-outcomes-research
   Google Scholar
• Cutsem EV, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as First-Line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–2019.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(7):1346–1355.
   PubMed Web of Science ®Google Scholar
• Ma X, Long L, Moon S, et al. Comparison of population characteristics in Real-World clinical oncology databases in the US: flatiron health. SEER and NPCR. medRxiv. 2020.
   Google Scholar
• Sacco JJ, Botten J, Macbeth F, et al. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One. 2010;5(1):e8933.
   PubMed Web of Science ®Google Scholar
• Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Nutrition. 1989;5(5):303–311.
   PubMed Web of Science ®Google Scholar
• Fryar CD, Kruszon-Moran D, Gu Q, et al. Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999–2000 through 2015–2016. Natl Health Stat Rep. 2018;(122):1–16.
   PubMedGoogle Scholar
• Vectibix (Panitumumab). [Internet] US prescribing information [updated]. 2017. [Jun cited 2021 Mar 23]. Available from: https://www.pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/vectibix/vectibix_pi.pdf
   Google Scholar
• IBM [Internet]. IBM Micromedex. Red book [cited 2021 Mar 23]. In Truven health analytics/IBM Watson health. 2021. Available from https://www.ibm.com/products/micromedex-red-book
   Google Scholar
• CMS [Internet]. Physician fee schedule. 2021. [updated 2021 Jan 20; cited 2021 Feb 11]. Available from https://www.cms.gov/medicare/physician-fee-schedule/search. [Internet]. [cited accessed 11 February 2021]. Available from: https://www.cms.gov/medicare/physician-fee-schedule/search
   Google Scholar
• NCCN: Antiemesis: NCCN clinical practice guidelines in oncology. Version 12021-December 23, 2020. [accessed on April 20].
   Google Scholar
• CMS CfMMS. Clinical laboratory fee schedule-2021. Baltimore (MD): Centers for Medicare & Medicaid Services; 2021. [Internet].
   Google Scholar
• Johns Hopkins Health System and Office of Johns Hopkins Physicians. Injection and infusion services coding in. 2019. [accessed 11 February 2021]. Available from https://www.hopkinsmedicine.org/compliance/forms/infusion-guideline-092020.pdf
   Google Scholar
• Solutions SM. Coding rules for chemotherapy administration and non-chemotherapy injections and infusion services. 2021. [accessed 11 February 2021]. Available from https://www.choptx.org/wp-content/uploads/2017/12/Coding-for-Oncology-Presentation-Final.v2pptx.pdf
   Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–4705.
   PubMed Web of Science ®Google Scholar
• Foley KA, Wang PF, Barber BL, et al. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann Oncol. 2010;21(7):1455–1461.
   PubMed Web of Science ®Google Scholar
• Lacouture ME. Prevention and treatment of acneiform rash caused by EGFR inhibitors. The Asco Post. 2021. [accessed 11 February 2021]. Available from https://ascopost.com/issues/may-15-2013/prevention-and-treatment-of-acneiform-rash-caused-by-egfr-inhibitors/
   Google Scholar
• U.S. Bureau of Labour Statistics CPI Inflation Calculator [Internet]. Available from https://www.bls.gov/data/inflation_calculator.htm
   Google Scholar
• Hess LM, Cui ZL, Mytelka DS, et al. Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA. Int J Colorectal Dis. 2019;34(4):581–588.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Sun W. Options for second-line treatment in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2016;14(1):46–54.
   PubMed Web of Science ®Google Scholar
• Cutsem EV, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. J Clin Oncol. 2010;28(15):3570–3570.
   PubMed Web of Science ®Google Scholar
• Akdeniz N, Kaplan MA, Uncu D, et al. The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study. Int J Colorectal Dis. 2021;36(6):1311–1319.
   PubMed Web of Science ®Google Scholar